August 6, 2025PLoS ONEOpen Access

Precision medicine in rheumatoid arthritis: Evaluation of a new approach to predict clinical response to methotrexate in patients with early rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

AEAlejandro Escudero‐ContrerasInstituto Maimónides de Investigación Biomédica de Córdoba MAMercedes AlpériCentral University Hospital of Asturias ATAna Isabel TurriónUniversidad de Salamanca

Discussion

Member takes

Implication

Prospective study evaluates predictive tests for clinical remission in rheumatoid arthritis patients on methotrexate, indicating the potential for improved treatment strategies.

Key Points

Precision medicine can enhance treatment outcomes in rheumatoid arthritis by predicting response to methotrexate.
In a study of 31 patients, 71% achieved clinical remission within 6 months using predictive tests.
Measurements of reactive oxygen species and monocyte activity effectively predicted remission, with high accuracy (AUCs of 0.919 and 0.826).
Identifying patients who will respond to methotrexate allows for better treatment planning during early stages of rheumatoid arthritis.

Cite This Study

Escudero‐Contreras et al. (2025) studied this question.

synapsesocial.com/papers/689522069f4f1c896c42932f https://doi.org/10.1371/journal.pone.0329440

View Full Paper

Ask AI

Bookmark

Implication

Prospective study evaluates predictive tests for clinical remission in rheumatoid arthritis patients on methotrexate, indicating the potential for improved treatment strategies.

Precision medicine in rheumatoid arthritis: Evaluation of a new approach to predict clinical response to methotrexate in patients with early rheumatoid arthritis

Discussion

Member takes

Implication

Key Points

Cite This Study

Precision medicine in rheumatoid arthritis: Evaluation of a new approach to predict clinical response to methotrexate in patients with early rheumatoid arthritis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider